What Avinnogen does

Avinnogen Co., Ltd. is a privately held South Korean biotechnology company founded in 2022 as a faculty spin-out from Seoul National University, headquartered at the SNU campus in Gwanak-gu, Seoul, with a second R&D facility opened in Bundang in October 2025. The company develops and applies a proprietary Primordial Germ Cell (PGC)-mediated gene editing platform for avian species, producing three lines of business: custom gene-edited chickens used as models and antibody-producing lines, an egg bioreactor platform that uses gene-edited chicken eggs as living bioreactors to manufacture therapeutic proteins and antibodies with human-like glycosylation, and high-value functional eggs (nutrient-fortified and low-cholesterol variants). Two internal pipeline candidates — AVN-001 for autoimmune disease therapy and AVN-002 for recombinant blood factor production — are in preclinical development using the same platform.

The company monetizes primarily through professional-services engagements for custom gene-edited chicken production (deliverables and IP transfer exclusively to the client), with stated but undisclosed licensing economics for egg bioreactor-derived protein production, and longer-term consumer upside through enhanced nutritional egg products. Customers are described by vertical — pharmaceutical and biotechnology research institutions for antibody and disease-model work, pharmaceutical companies seeking cost-effective protein production, and food and agricultural buyers for functional eggs — but no named customer logos or contracted revenue were disclosed, and pricing is not publicly listed; all commercial engagement runs through inquiry-based contact channels. Distribution is direct, enterprise, and global in stated scope, with primary operating geography in South Korea.

Avinnogen is operating in early-stage, grant-and-services mode rather than commercial-revenue mode. The company has secured multiple Korean government non-dilutive programs (TIPS in August 2024, Young Researcher Support in June 2023, IP-R&D Strategy Support in 2024 and 2025, Regional Industry Promotion in 2024), earned Venture Company and Startup Business certifications, received an undisclosed investment round from Mira Partners Individual Investment Association and JOIN Co., Ltd. in August 2025, and in July 2025 hired its first disclosed CTO (Hongjo Lee) and CSO/Executive Vice President (Youngmin Kim). The combination of an academic-originated proprietary biological platform, preclinical-stage therapeutic pipeline, services-based near-term revenue model, and reliance on Korean public funding programs characterizes a typical Korean preclinical spin-out building toward an inflection point rather than a commercial-stage business.

Name

Avinnogen

Legal name

Avinnogen Co., Ltd.

Website

https://avinnogen.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

Avinnogen is a South Korean preclinical biotechnology company that uses proprietary avian primordial germ cell gene editing to produce custom gene-edited chickens, an egg-based bioreactor for therapeutic proteins, and high-value functional eggs for pharmaceutical and food-industry customers.

Ownership category

akta.pro rank

Product category

Avian Biotechnology and Biopharmaceutical Manufacturing

NAICS

Poultry Hatcheries (112340), Other Poultry Production (11239)

SIC

Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro primary industry

Biotechnology & Gene-Edited Trait Development (AFAGAIAG)

akta.pro secondary industries

Hatcheries & Chick Production (Day-Old Chicks, Pullets) (AFAEADAD), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)

Keywords

• Avian gene editing
• Therapeutic protein production
• Egg bioreactor platform
• Biopharmaceutical manufacturing
• Recombinant antibody production

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Custom Gene-Edited Chicken Production Services: Custom gene-edited chicken production services for various research and commercial purposes including antibody production, disease-resistant breed development, embryology research, human disease modeling, and drug development. Deliverables and IP from start to finish belong exclusively to the client.
2. Egg Bioreactor Protein Production: Therapeutic protein and antibody production using gene-edited eggs as bioreactors. Products include AVN-001 for autoimmune disease therapy and AVN-002 for recombinant blood factor production.
3. High-Value Egg Products: Functional enhanced egg products with improved nutritional profiles including nutrient-fortified eggs and low-cholesterol eggs that overcome limitations of conventional eggs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Avinnogen produces gene-edited birds and useful substances using its proprietary avian Primordial Germ Cell (PGC)-mediated gene editing platform. Its commercial offerings include custom gene-edited chicken production services for antibody production and disease modeling, an egg bioreactor platform for manufacturing therapeutic proteins and antibodies with human-like glycosylation, and high-value functional egg products such as nutrient-fortified and low-cholesterol eggs. The company also develops pipeline therapeutic candidates AVN-001 and AVN-002.

Product overview

Avinnogen is a biotechnology company offering a portfolio of avian gene-editing products and services centered on its proprietary PGC (Primordial Germ Cell) technology platform. The core offerings include Gene-Edited Chicken production services for antibody production and disease research, an Egg Bioreactor platform for therapeutic protein manufacturing, and High-Value Eggs as functional food products. The company also maintains a pipeline of therapeutic candidates including AVN-001 for autoimmune disease and AVN-002 for recombinant blood factor production, developed through gene-edited chicken systems.

Differentiator

Problem solved

Functional benefit

Products and services

• Gene-Edited Chicken Production Service Custom gene-edited chicken production services using Avinnogen's proprietary PGC-mediated gene editing technology. Delivered to pharmaceutical companies, biotech firms, and research institutions for antibody production, recombinant protein platforms, disease-resistant breed development, embryology and gene function research, human disease modeling, and drug development. All deliverables and IP from start to finish belong exclusively to the client.
• Egg Bioreactor Platform Next-generation biomanufacturing platform that uses gene-edited chicken eggs as living production facilities to mass-produce high-quality therapeutic proteins and antibodies with human-like glycosylation and minimized immune response, supplied to pharmaceutical companies for therapeutic protein production.
• High-Value Functional Eggs Functional enhanced egg products developed through gene editing technology, including nutrient-fortified eggs and low-cholesterol eggs, designed to overcome the nutritional limitations of conventional eggs for food and agricultural industry customers.

Quantifiable outcome

• Industry-leading gene-edited success rates
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Gangwon TechnoparkminorImplementation/ SI/ Consulting Partner · 1 July 2024Selected for Gangwon Technopark Business Support Program providing regional industry promotion and business support services.
• Korea Intellectual Property Strategy AgencyminorImplementation/ SI/ Consulting Partner · 1 May 2024Selected for IP-R&D Strategy Support Project to develop intellectual property strategy and support R&D activities.
• Korea Industrial Technology Association (KOITA)minorStrategic or Co-development Partner · 1 September 2022Established an affiliated research institute registered with the Korea Industrial Technology Association (KOITA), establishing formal research institute status.
• Seoul National UniversitycoreStrategic or Co-development Partner · 1 March 2022Received faculty startup approval from Seoul National University, establishing the company's origins as a university spin-off with research foundation.

Scale indicators4 records

Recent moves12 records

Expansion highlights5 records

Broad incumbents

• Cobb-Vantress: Major poultry breeding company owned by Tyson Foods; competes in the same broiler breeding value chain that Avinnogen's disease-resistant breed development targets.
• Genus plc: Global animal genetics company with significant poultry and swine lines; a broad incumbent in the same end-market (animal production genetics) and the most likely strategic acquirer or licensing partner for Avinnogen's platform.
• Hendrix Genetics: Multispecies animal breeding company with substantial poultry genetics operations; a broad incumbent in the gene-edited poultry space where Avinnogen competes.
• Aviagen: World's leading poultry breeding company producing broiler and layer genetic lines; comparable to Avinnogen's gene-edited chicken production services in target customer and use case.

Direct peers

• Recombinetics: Animal gene editing company focused on livestock genetics and biomedical applications, including disease resistance traits — overlapping with Avinnogen's gene-edited bird and disease-resistant breed work.
• Roslin Technologies: University of Edinburgh spin-out commercializing transgenic avian technologies for biopharma, including egg-based protein production — directly comparable to Avinnogen's PGC-mediated platform and egg bioreactor strategy.
• Crystal Biosciences (Ligand Pharmaceuticals): Develops monoclonal antibodies using transgenic chicken egg platforms (OmniAb). Most direct global competitor to Avinnogen's egg bioreactor therapeutic protein approach.

Regional players

• Samsung Biologics: World's largest contract biologics manufacturer based in South Korea; the dominant Korean and global CMO that Avinnogen would compete with or supply into for therapeutic protein production.
• Celltrion: Korean biopharmaceutical manufacturer producing biosimilars and biologics at large scale; a regional incumbent defining the Korean biomanufacturing competitive landscape Avinnogen's egg bioreactor must enter.

Emerging players

• Precigen: Biotech using advanced gene and cell engineering for therapeutic and industrial bioproduction; an emerging platform competitor with similar gene-based bio-production technology to Avinnogen's PGC platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avinnogen